Several clinical trials have been conducted to test the safety and efficacy of arthritis-modifying candidate drugs that reduced aggrecanase activity, i.e., inhibited ADAMTS4 and ADAMTS5 in preclinical studies. Here, ADAMTS4 is linked to Arthritis.